X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7595) 7595
Magazine Article (20) 20
Book Chapter (5) 5
Book / eBook (3) 3
Web Resource (3) 3
Newsletter (2) 2
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6000) 6000
male (3979) 3979
female (3598) 3598
imidazoles - adverse effects (3330) 3330
imidazoles - therapeutic use (3227) 3227
middle aged (2654) 2654
aged (2126) 2126
imidazoles - administration & dosage (2081) 2081
animals (2045) 2045
adult (2016) 2016
imidazoles - pharmacology (1776) 1776
treatment outcome (1113) 1113
pharmacology & pharmacy (982) 982
oncology (944) 944
diphosphonates - adverse effects (823) 823
zoledronic acid (731) 731
diphosphonates - therapeutic use (705) 705
double-blind method (676) 676
rats (652) 652
dose-response relationship, drug (648) 648
aged, 80 and over (647) 647
bone density conservation agents - adverse effects (592) 592
cancer (583) 583
drug therapy, combination (570) 570
hypertension - drug therapy (563) 563
diphosphonates - administration & dosage (556) 556
time factors (552) 552
care and treatment (523) 523
analysis (522) 522
drug therapy (512) 512
bone density conservation agents - therapeutic use (503) 503
mice (492) 492
bisphosphonates (476) 476
double-blind (470) 470
blood pressure - drug effects (463) 463
therapy (458) 458
adolescent (454) 454
imidazoles - pharmacokinetics (451) 451
medicine & public health (445) 445
research (438) 438
risk factors (424) 424
efficacy (401) 401
antineoplastic agents - adverse effects (398) 398
administration, oral (397) 397
antihypertensive agents - therapeutic use (396) 396
clinical trials as topic (390) 390
hypertension (390) 390
health aspects (378) 378
bone density conservation agents - administration & dosage (374) 374
drug administration schedule (365) 365
bone neoplasms - secondary (364) 364
osteoporosis (362) 362
antihypertensive agents - adverse effects (359) 359
tetrazoles - therapeutic use (358) 358
medicine, general & internal (348) 348
prospective studies (341) 341
antineoplastic agents - therapeutic use (340) 340
tetrazoles - adverse effects (340) 340
safety (319) 319
follow-up studies (314) 314
vardenafil dihydrochloride (313) 313
piperazines - therapeutic use (302) 302
toxicology (302) 302
bone neoplasms - drug therapy (299) 299
endocrinology & metabolism (290) 290
urology & nephrology (287) 287
clinical trials (283) 283
imidazoles - toxicity (276) 276
young adult (275) 275
imidazoles (272) 272
abridged index medicus (268) 268
apoptosis (262) 262
pyridines - pharmacology (262) 262
neonicotinoids (259) 259
hepatitis c, chronic - drug therapy (254) 254
imidazoles - chemistry (253) 253
piperazines - adverse effects (253) 253
chemotherapy (250) 250
randomized controlled trials as topic (249) 249
disease models, animal (248) 248
metastasis (247) 247
surgery (247) 247
retrospective studies (246) 246
diphosphonates - pharmacology (241) 241
prevention (240) 240
expression (239) 239
pharmacokinetics (239) 239
in-vitro (236) 236
internal medicine (236) 236
osteonecrosis - chemically induced (230) 230
breast neoplasms - drug therapy (228) 228
infusions, intravenous (228) 228
dosage and administration (226) 226
antineoplastic combined chemotherapy protocols - therapeutic use (225) 225
dogs (223) 223
gastroenterology & hepatology (223) 223
melanoma - drug therapy (223) 223
toxicity (223) 223
bisphosphonate (222) 222
erectile dysfunction - drug therapy (221) 221
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7120) 7120
German (190) 190
French (116) 116
Japanese (109) 109
Spanish (55) 55
Russian (41) 41
Italian (33) 33
Chinese (29) 29
Portuguese (19) 19
Dutch (15) 15
Danish (11) 11
Hungarian (9) 9
Swedish (7) 7
Czech (6) 6
Norwegian (6) 6
Polish (6) 6
Bulgarian (3) 3
Romanian (2) 2
Serbian (2) 2
Finnish (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Journal Article
Clinical journal of the American Society of Nephrology, ISSN 1555-9041, 01/2017, Volume 12, Issue 1, pp. 176 - 189
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment... 
BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | METASTASES | DELTA T-CELLS | RECEPTOR | ADJUVANT THERAPY | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Gastrointestinal endoscopy, ISSN 0016-5107, 2014, Volume 79, Issue 1, pp. 140 - 150
.... Reducing the incidence of adverse effects requires an appropriate index of suspicion and good communication between the gastroenterologist and pathologist, both of which can significantly impact patient care. Copyright © 2014 by the American Society for Gastrointestinal Endoscopy. 
Gastroenterology and Hepatology | cyclooxygenase | mycophenolate mofetil | COX | NSAID | MMF | nonsteroidal anti-inflammatory drug | INFLAMMATORY-BOWEL-DISEASE | LARGE-INTESTINE TRANSIT | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DIAPHRAGM DISEASE | ULCERATIVE-COLITIS | SLOUGHING ESOPHAGITIS | SODIUM POLYSTYRENE SULFONATE | MELANOSIS COLI | UPPER GASTROINTESTINAL-TRACT | GASTROENTEROLOGY & HEPATOLOGY | MYCOPHENOLATE-MOFETIL | Cathartics - adverse effects | Intestinal Diseases - chemically induced | Humans | Imidazoles - adverse effects | Antibodies, Monoclonal - adverse effects | Esophagitis - chemically induced | Stomach Diseases - chemically induced | Stomach Diseases - pathology | Colchicine - adverse effects | Ion Exchange Resins - adverse effects | Iron - adverse effects | Esophagitis - pathology | Laxatives - adverse effects | Adrenal Cortex Hormones - adverse effects | Mycophenolic Acid - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Mycophenolic Acid - analogs & derivatives | Ergotamine - adverse effects | Antineoplastic Agents - adverse effects | Contraceptives, Oral - adverse effects | Tetrazoles - adverse effects | Diuretics - adverse effects | Intestinal Diseases - pathology | Olmesartan Medoxomil | Gastrointestinal system
Journal Article
Seminars in diagnostic pathology, ISSN 0740-2570, 2014, Volume 31, Issue 2, pp. 165 - 175
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2012, Volume 39, Issue 4, pp. 388 - 401
Abstract Background To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management... 
Hematology, Oncology and Palliative Medicine | Side effects | Adverse events | Targeted therapy | Renal cell carcinoma | MAMMALIAN TARGET | SUNITINIB TREATMENT | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | KINASE INHIBITORS | INTERFERON-ALPHA | ONCOLOGY | RANDOMIZED PHASE-II | NASAL-SEPTUM PERFORATION | QUALITY-OF-LIFE | JAPANESE PATIENTS | FOOT SKIN REACTION | Niacinamide - analogs & derivatives | Humans | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Protein Kinase Inhibitors - adverse effects | Bevacizumab | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Molecular Targeted Therapy - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Imidazoles - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Care and treatment | Metastasis | Carcinoma, Renal cell | Cancer | Index Medicus
Journal Article